CERo Therapeutics Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.2K
- Price
- $0.00925
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.63%
- Volume
- 571.2K
About
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding1.2M
Computed float993.1K
Float / shares82.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001870404
Websitehttps://www.cero.bio
AI Summary
AI-generated1/4
standardbullishdebt offering
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
SRX Global purchased senior secured debt in CERo Therapeutics, providing capital to accelerate the advancement of its clinical programs.
In the ongoing Phase 1 CERTAIN-T trial, CERo has treated six patients to date, with no dose-limiting toxicities observed in the most recent cohort at an increased dose level.
The company has initiated the third planned cohort, expected to evaluate a protocol of one billion cells per patient and expand into MDS and myelofibrosis indications.